Open AccessReview
Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors
by
Lisa M. Kenney
Lisa M. Kenney 1
and
Marybeth Hughes
Marybeth Hughes
Marybeth Hughes, MD, FACS, joins EVMS Surgery as Chief of Surgical Oncology. Previously, she served [...]
Marybeth Hughes, MD, FACS, joins EVMS Surgery as Chief of Surgical Oncology. Previously, she served as a Surgical Oncologist at The Surgery Branch and the Thoracic and Gastrointestinal Oncology Branch Center for Cancer Research at the National Cancer Institute, National Institutes of Health (NIH), in Bethesda Maryland. There, she was also Director for the Surgical Oncology Research Fellowship Program. Dr. Hughes is certified by the American Board of Surgery, a Fellow of the American College of Surgeons, an Advanced Trauma Life Support Instructor and a DaVinci Robotic Console Surgeon. Dr. Hughes has served as principal investigator and associate investigator for various clinical trials at NIH on cancer-related protocols. Her work has been published in numerous journals and books on surgical oncology topics, most notably related to neuroendocrine tumors, melanoma liver metastases, pancreatic cancer, adenocarcinoma of the appendix, colorectal cancers, and breast cancer. Dr. Hughes is a national and international presenter on surgical oncology topics and continues to teach and mentor medical students, residents, and fellows in surgical oncology. While at the NIH, Dr. Hughes re-developed the curriculum for the Surgical Oncology Research Fellowship Program and taught Advanced Trauma Life Support for the Department of Defense.
2,*
1
Department of Surgery, Eastern Virginia Medical School, Macon and Joan Brock Virginia Health Sciences at Old Dominion University, 825 Fairfax Avenue, Suite 610, Norfolk, VA 23507, USA
2
Department of Surgery, Division of Surgical Oncology, Eastern Virginia Medical School, Macon and Joan Brock Virginia Health Sciences at Old Dominion University, 825 Fairfax Avenue, Suite 610, Norfolk, VA 23507, USA
*
Author to whom correspondence should be addressed.
Submission received: 14 December 2024
/
Revised: 17 January 2025
/
Accepted: 22 January 2025
/
Published: 23 January 2025
Simple Summary
This review article discusses the surgical management of neuroendocrine tumors (NETs), a heterogeneous group of malignancies that often originate in the gastroenteropancreatic tract. Clinical outcomes in patients with NETs depend on tumor grade, size, and metastatic stage. Tailored surgical strategies such as endoscopic or formal surgical resection vary based on tumor grade and organ of origin, and can play a curative role in localized diseases. Additionally, cytoreduction surgery, liver-directed therapies, or liver transplants are options for symptom management and underscore the importance of a multidisciplinary approach.
Abstract
Background/Objectives: Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from enterochromaffin cells that can arise from the gastrointestinal (GI) tract and pancreas. Surgical management is the cornerstone of treatment, with the optimal approach tailored by tumor grade, size, location, and presence of metastasis. This review discusses the current strategies for the surgical management of NETs of the gastroenteropancreatic tract. Methods: A review of the available literature was conducted to evaluate surgical approaches to NETs. Consensus guidelines were incorporated to synthesize evidence-based recommendations. Results: For gastric NETs, surgical approach depends on Rindi Classification, WHO grade, and tumor size, with endoscopic approaches favored for smaller and low-grade lesions. Small bowel NETs can be multifocal and thus often require a surgical approach with careful evaluation of the entire intestine. Pancreatic NETs are categorized as functional or non-functional, with enucleation or formal resection strategies based on size, location, functional status, and risk of malignancy. Colorectal NETs are primarily treated with transanal localized or formal surgical resection, depending on lesion size and depth of invasion or presence of lymph node involvement. Appendiceal NETs are either treated with appendectomy or right hemicolectomy, depending on the size, location, and invasiveness of the lesions. For metastatic NETs, cytoreduction, liver transplantation, and targeted therapies offer symptom relief and possible survival benefits. Conclusions: Surgical resection provides curative potential for localized NETs and symptom control in metastatic cases. Future research is essential to refine guidelines for intermediate-risk lesions and multifocal tumors, ensuring optimal outcomes for patients with gastroenteropancreatic NETs.
Share and Cite
MDPI and ACS Style
Kenney, L.M.; Hughes, M.
Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors. Cancers 2025, 17, 377.
https://doi.org/10.3390/cancers17030377
AMA Style
Kenney LM, Hughes M.
Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors. Cancers. 2025; 17(3):377.
https://doi.org/10.3390/cancers17030377
Chicago/Turabian Style
Kenney, Lisa M., and Marybeth Hughes.
2025. "Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors" Cancers 17, no. 3: 377.
https://doi.org/10.3390/cancers17030377
APA Style
Kenney, L. M., & Hughes, M.
(2025). Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors. Cancers, 17(3), 377.
https://doi.org/10.3390/cancers17030377
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.